SCHEMBL16626178

SCHEMBL16626178

c1ccc(-c2ccc3c(N4CCCCC4)nc(-n4cccn4)nc3c2)cc1

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 11/20 0.67
L3MBTL1 Q9Y468 2/20 0.52
GLA P06280 1/20 0.52
TSHR P16473 1/20 0.52
HSD17B10 Q99714 1/20 0.52
GAA P10253 1/20 0.52
HPGD P15428 1/20 0.52
ADORA2A P29274 3/20 0.51
HRH4 Q9H3N8 1/20 0.48
ACP1 P24666 1/20 0.47
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPT P10636 1/20 0.45
MAPK1 P28482 1/20 0.45
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16626193 0.99 EGLN1 (0.67) EGLN1L3MBTL1GLATSHRHSD17B10
SCHEMBL16626172 0.92 EGLN1 (0.67) EGLN1L3MBTL1GLATSHRHSD17B10
SCHEMBL16626253 0.92 EGLN1 (0.67) EGLN1L3MBTL1GLATSHRHSD17B10
SCHEMBL16626176 0.91 EGLN1 (0.66) EGLN1L3MBTL1GLATSHRHSD17B10
SCHEMBL16626201 0.84 EGLN1 (0.68) EGLN1L3MBTL1GLATSHRHSD17B10
SCHEMBL16626219 0.84 EGLN1 (0.68) EGLN1L3MBTL1GLATSHRHSD17B10
SCHEMBL627349 0.82 EGLN1 (0.67) EGLN1L3MBTL1GLATSHRHSD17B10
SCHEMBL626747 0.82 EGLN1 (0.70) EGLN1ADORA2AHRH4KDM4EALDH1A1
SCHEMBL16626264 0.81 EGLN1 (0.68) EGLN1GLAGAAHPGDKDM4E
SCHEMBL16626156 0.81 EGLN1 (0.68) EGLN1L3MBTL1ADORA2AMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10975062-B2 4-aminoquinazolinyl compounds as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV 2021-04-13 US disclosed
US-20200095234-A1 4-AMINOQUINAZOLINYL COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2020-03-26 US disclosed
US-9006251-B2 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors JANSSEN PHARAMCEUTICA NV (BE) 2015-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10975062-B2 4-aminoquinazolinyl compounds as prolyl hydroxylase inhibitors P4HA1, EGLN3, EGLN2 EGLN1 6/4885L3MBTL1 3221/4885GLA 1393/4885
US-20200095234-A1 4-AMINOQUINAZOLINYL COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS P4HA1, EGLN3, EGLN2 EGLN1 6/4885L3MBTL1 3221/4885GLA 1393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.